Evidence map›Paper›PMID 41705856›Full record

ArticleAntimicrobial agents and chemotherapy2026

Ιdentification of SQ109 analogs with enhanced antimicrobial activity against methicillin-resistant

Charilaos Dellis, George Laros, Kyriakos Georgiou, Liyang Zhang, Lewis Oscar Felix, Nikolas Naziris, Narchonai Ganesan, Jianhua Gu, Marianna Stampolaki, Costas Demetzos and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Charilaos DellisDepartment of Medicine, Houston Methodist Hospital, Houston, Texas, USA.ORCID 0000-0001-6195-0999
George LarosLaboratory of Medicinal Chemistry, Section of Pharmaceutical Chemistry, Department of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece.
Kyriakos GeorgiouLaboratory of Medicinal Chemistry, Section of Pharmaceutical Chemistry, Department of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece.
Liyang ZhangDepartment of Medicine, Houston Methodist Hospital, Houston, Texas, USA.
Lewis Oscar FelixDepartment of Medicine, Houston Methodist Hospital, Houston, Texas, USA.
Nikolas NazirisSection of Pharmaceutical Technology, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Athens, Greece.
Narchonai GanesanDepartment of Medicine, Houston Methodist Hospital, Houston, Texas, USA.
Jianhua GuElectron Microscopy Core, Houston Methodist Academic Institute, Houston, Texas, USA.
Marianna StampolakiLaboratory of Medicinal Chemistry, Section of Pharmaceutical Chemistry, Department of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece.
Costas DemetzosSection of Pharmaceutical Technology, Department of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, Athens, Greece.
Ioannis P PapanastasiouLaboratory of Medicinal Chemistry, Section of Pharmaceutical Chemistry, Department of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece.
Biswajit MishraDepartment of Medicine, Houston Methodist Hospital, Houston, Texas, USA.
Antonios KolocourisLaboratory of Medicinal Chemistry, Section of Pharmaceutical Chemistry, Department of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece.ORCID 0000-0001-6110-1903
Eleftherios MylonakisDepartment of Medicine, Houston Methodist Hospital, Houston, Texas, USA.ORCID 0000-0002-4624-0777

Funding

Technical Mother Machine CoreP01AI083214 · NIAID · SCHEPENS EYE RESEARCH INSTITUTE · PI David C Hooper · 2009 to 2026
$39.4M
Chiesi Hellas 10354NIAID NIH HHS P01 AI083214
6 · The paper itself

Abstract

The rise of antimicrobial resistance necessitates the development of novel or repurposed molecules with potent antibacterial properties. In this study, we evaluated the lipid-based antimicrobial candidate, SQ109, and 14 of its analogs for their efficacy against methicillin-resistant

Indexed as

AdamantaneAnti-Bacterial AgentsMethicillin-Resistant Staphylococcus aureusCell MembraneEthylenediaminesGentamicinsMicrobial Sensitivity TestsMolecular Dynamics SimulationProton-Motive ForceAdamantaneAnti-Bacterial AgentsEthylenediaminesGentamicinsN-geranyl-N'-(2-adamantyl)ethane-1,2-diamineanti-staphylococcalgram-positiveMRSApersistersS. aureusSQ109

Identifiers

PMID41705856
PMCPMC13041356

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.